Pipeline Publications

PentaStaph Publications

Benjamin DK, Schelonka R, White R, Holley, HP, Bifano E, Cummings J, Adcock K, Kaufman D, Puppala B, Riedel P, Hall B, White J, Cottom CM. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol. 2006 May; 26(5):290-5.

Roghmann M, Taylor KL, Gupte A, Zhan M, Johnson JA, Cross A, Edelman R, Fattom AI. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. 2005. J Hosp Infect. 2005 Jan; 59 (1):27-32.

Fatton A, Fuller S, Popst M, Winston S, Muenz L, He D, Naso R, Horwith G. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX?) in hemodialysis patients. Vaccine. 2004 Dec 16;23(5):656-63. 

Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX?, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine. 2004 Feb 17;22(7):880-7.

Walker RI, Blanchard T, Braun JM, et.al. Meeting summary: possibilities for active and passive vaccination against opportunistic infections. 2004. Vaccine 2004 Feb 17;22(7):801-4.

Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines . Am Heart J. 2004 Apr;147(4):593-8.

Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002 Feb 14;346(7):491-6.

O'Brien CN, Guidry AJ, Fattom A, Shepherd S, Douglass LW, Westhoff DC. Production of antibodies to Staphylococcus aureus serotypes 5, 8 and 336 using poly (DL-lactide-co-glycolide) microspheres. J Diary Sci. 2000 Aug;83(8):1758-66.

Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med. 1999 Apr;27(4):798-801.

Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitopic overload at the site of injection may result in suppression of the immune resonse to combined capsular polysaccharide conjugate vaccines. Vaccine. 1999 Jan;17(2):126-33.

Guidry A, Fattom A, Patel A, O'Brien C, Shepherd S, Lohuis J. Serotyping scheme for Staphylococcus aureus isolated from cows with mastitis. Am J Vet Res. 1998 Dec;59(12):1537-9.

Fattom AI, Sarwar J, Basham L, Ennifar S, Naso R. Antigenic determinants of Staphylococcus aureus type 5 and 8 capsular polysaccharide vaccines. Infect Immun. 1998 Oct;66(10):4588-92.

Essawi T, Na'was T, Hawwari A, Wadi S, Doudin A, and Fattom AI. Molecular, antibiogram and serological typing of Staphylococcus aureus isolates recovered from Al-Makased hospital in East Jerusalem. Trop Med Int Health. 1998 Jul;3(7):576-83.

Sood RK, Fattom A. Capsular polysaccharide-protein conjugate vaccines and intravenous imunoglobulins. Expert Opin Investig Drugs. 1998 Mar;7(3):333-47

Berg S, Kasvi S., Trollfors B, Pilichowska-Paszkiet J, Fattom A, Tessin I, Lagergard T. Antibodies to group B streptococci in neonates and infants. Eur J Pediatr. 1998 Mar;157(3):221-4.

Na'was T, Hawwari A, Hendrix A, Hebden J, Edelman R, Martin M, Campbell W, Naso, R, Schwalbe R, and Fattom, AI. Phenotypic and genotypic characterization of nosocomial S. aureus isolates from trauma patients.  J Clin Microbiol. 1998 Feb;36(2):414-20.

Guidry A, Fattom A, Patel A, O'Brien C. Prevalence of capsular serotypes among Staphylococcus aureus isolates from cows with mastitis in the United States. Vet Microbiol. 1997 Dec;59(1):53-8.

Lee JC, Park JS, Shepherd SE, Carey V,  Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats.  Infect Immun. 1997 Oct;65(10):4146-51.

Fattom AI, Naso R. Staphylococcus aureus vaccination for dialysis patients--an update. Adv Ren Replace Ther. 1996 Oct;3(4):302-8.

Fattom AI, Sarwar J, Ortiz A, and Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun. 1996 May; 64(5):1659-65.

Kotloff KL, Fattom A , Basham L, Hawwari A, Harkonen S, Edelman R. Safety and immunogenicity of a tetravalent group B Streptococcal polysaccharide vaccine in healthy adults.  Vaccine 1996 Apr;14(5):446-50.

Basham LE, Pavliak V, Li X, Hawwari A, Kotoloff KL, Edelman R, Fattom A. A simple, quantitative, reproducible avidin-biotin ELISA for the evaluation of group B streptococcus type-specific antibodies in humans. Vaccine.  1996 Apr;14(5):439-45.

Welch PG, Fattom A, Moore JJr, Schneerson R, Shiloach J, Bryla DA, Li X, and Robbins JB. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol. 1996 Feb;7(2):247-53.

Fattom AI, Naso R. Staphylococcal vaccines: a realistic dream? Ann Med. 1996 Feb; 28(1):43-6.

Naso R, Fattom A.   Polysaccharide conjugate vaccines for the prevention of Gram-positive bacterial infections. Adv Exp Med Biol. 1996;397:133-40.

Fattom A, Li X, Cho YH, Burns A, Hawwari A, Shepherd SE, Coughlin R, Winston S, Naso R. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine. 1995 Oct;13(14):1288-93.

Robbins JB, Schneerson R, Vann WF, Bryla DA, Fattom A. Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines. Ann N Y Acad Sci. 1995 May 31;754:68-82.

Fattom, A.  Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man.  Adv Exp Med Biol. 1995;383:131-9.

Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus types 5 and 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun. 1993 Mar; 61(3):1023-32.

Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, Robbins JB, Schneerson R. Comparative immunogenicity of conjugates composed of Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pryidildithio) propionate. Infect Immun. 1992 Feb;60(2):584-9.

Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990 Jul;58(7):2367-2374.

NicVAX Publications

Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, deVos A, Horwith G, Pentel, P. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005 Nov;78(5):456-67.

Malin DH, Alvarado CL, Woodhouse KS, Karp H, Urdiales E, Lay D, Appleby P, Moon WD, Ennifar S, Basham L, Fattom A. Passive Immunization against nicotine attenuates nicotine discrimination.  Life Sci. 2002 Apr 26;70(23):2793-8.

Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, Chandrasekara H, Alvarado CL, Hieda Y, Keyler DE, Pentel PR, Ennifar S, Basham LE, Naso R, Fattom A. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav. 2001 Jan: 68(1):87-92.

Tuncok Y, Hieda Y, Keyler DE, Brown S, Ennifar S, Fattom A, Pentel PR. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol. 2001 May;9(2):228-34.

Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain.  Int J Immunopharmacol. 2000 Oct;22(10):809-19.

Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effect in rats. Pharmacol Biochem Behav. 2000 Jan 1;65(1):191-8.

Staphylococcus epidermidis

Fattom A, Shepherd S, Karakawa W. Capsular polysaccharide serotyping scheme for Staphylococcus epidermidis. J Clin Microbiol. 1992 Dec;30(12):3270-3.